Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 2
2006 2
2007 1
2008 2
2009 1
2010 4
2011 7
2012 2
2013 1
2014 2
2016 1
2017 2
2018 1
2019 2
2020 3
2021 6
2022 4
2023 5
2024 6
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hájek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balarí A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Hungria V, et al. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15. Lancet Oncol. 2025. PMID: 40680754 Clinical Trial.
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Hungria V, et al. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15. Lancet Haematol. 2025. PMID: 40680752 Clinical Trial.
Presenting a conceptual model for designing hospital architecture with a patient-centered approach based on the patient's lived experience of sense of place in the therapeutic space.
Ghalehnoei MP, Massoud M, Yarmohammadian MH. Ghalehnoei MP, et al. J Educ Health Promot. 2022 Jun 30;11:188. doi: 10.4103/jehp.jehp_629_21. eCollection 2022. J Educ Health Promot. 2022. PMID: 36003256 Free PMC article.
They were hospitalized for at least 3 days in two hospitals (Dr. Pirooz in Lahijan and Ghaem in Rasht). The data were analyzed by the Colaizzi method. RESULTS: The results consisted of 530 primary codes, 57 subthemes, and 7 main themes. ...
They were hospitalized for at least 3 days in two hospitals (Dr. Pirooz in Lahijan and Ghaem in Rasht). The data were analyzed by the …
RETRACTION: Incidence Rate and Risk Factors of Surgical Wound Infection in General Surgery Patients: A Cross-Sectional Study.
[No authors listed] [No authors listed] Int Wound J. 2025 Mar;22(3):e70238. doi: 10.1111/iwj.70238. Int Wound J. 2025. PMID: 40000114 Free PMC article.
R. Asgary, M. Sarafi, N. Fathalipour, A. Pirooz, Z. Jafaryparvar, E. Rafiei, M. Farzin, P. Samidoust, and M. S. E. Delshad, "Incidence Rate and Risk Factors of Surgical Wound Infection in General Surgery Patients: A Cross-Sectional Study," International Wound Journal 20, n …
R. Asgary, M. Sarafi, N. Fathalipour, A. Pirooz, Z. Jafaryparvar, E. Rafiei, M. Farzin, P. Samidoust, and M. S. E. Delshad, "Incidenc …
55 results